A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Inclusion criteria:

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

- Histologically or cytologically confirmed, resectable Stage II, IIIA, or Select IIIB
(T3N2 only) NSCLC of squamous or non-squamous histology. Staging should be based on
the 8th edition of the AJCC/UICC staging system

- Evaluation by an attending thoracic surgeon to confirm eligibility for an R0 resection
with curative intent

- Adequate pulmonary and cardiac function to undergo surgical resection

- Measurable disease as defined by RECIST v1.1

- Adequate hematologic and end organ function

- Negative HIV test at screening

- Negative for active HBV and HCV at screening

- Adequate tissue for PD-L1 IHC assessment

Exclusion criteria:

- Any prior therapy for lung cancer

- Malignancies other than NSCLC within 5 years prior to randomization, with the
exception of those with a negligible risk of metastasis or death treated expected
curative outcome

- Non-squamous NSCLC histology with activating ALK and EGFR mutation

- Pregnant or lactating women

- History of autoimmune disease

- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
pneumonitis, or evidence of active of active pneumonitis on screening chest Computed
Tomography (CT) scan

- Prior treatment with cluster of differentiation 137 (CD137) agonist or immune
checkpoint blockade therapies, anti-programmed-death-1 (anti-PD-1), and anti-PD-L1
therapeutic antibody

- Severe infection within 4 weeks prior to randomization

- Significant history of cardiovascular disease